A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Thyroid Eye Disease Clinical Trial

— UplighTED  

Official title:

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06307626
• Other study ID #: ARGX-113-2309
• Secondary ID: 2023-509198-22-0
• Status: Recruiting
• Phase: Phase 3
• Start date: March 28, 2024
• Est. completion date: October 2027

Study information

• Verified date: June 2024
• Source: argenx
• Contact: Sabine Coppieters, MD
• Phone: 857-350-4834
• Email: clinicaltrials[@]argenx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.

After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks.

An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307613)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: October 2027
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The participant is at least 18 years of age

• The participant is capable of providing signed informed consent and following with protocol requirements

• The participant has a physician's diagnosis of active, moderate-to-severe thyroid eye disease (TED) associated with autoimmune thyroid conditions (Graves' disease or Hashimoto's thyroiditis) for the most severely affected eye

• The participant has onset of active TED symptoms within 12 months before screening

• The participant must have normal thyroid function with the baseline disease under control or have mild hypo or hyperthyroidism at screening. Every effort should be made to correct the mild hypo or hyperthyroidism promptly and to maintain the normal thyroid function for the full duration of the study

• The participant agrees to use birth control consistent with local regulations and the people of child-bearing potential must have a negative blood pregnancy test at screening and a negative urine pregnancy test before receiving the study drug

Exclusion Criteria:

• Optic neuropathy (damage to optic nerve), defined as new visual field defect (blind spot), relative afferent pupillary defect (pupils respond differently to light), or color defect secondary to optic nerve involvement within the 6 months before screening

• Corneal decompensation (swelling of the cornea) unresponsive to medical management

• Previous orbital irradiation or surgery for TED

• Use of some medications before screening (more information is found in the protocol)

• Known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of TED or puts the participant at undue risk

• History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for =3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer

• Clinically significant active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV

• Current participation in another interventional clinical study or previous participation in an efgartigimod clinical study and at least 1 dose of study drug received or has received at least 1 dose of commercially available efgartigimod

• Known hypersensitivity to study drug or one of its excipients (inactive ingredients)

• History of or current alcohol, drug, or medication abuse within 12 months before screening as assessed by the investigator

• Pregnant or lactating state or intention to become pregnant during the study

• Live or live-attenuated vaccine received <4 weeks before screening

The complete list of exclusion criteria can be found in the protocol.

Related Conditions & MeSH terms

• Eye Diseases
• Graves Ophthalmopathy
• Thyroid Diseases
• Thyroid Eye Disease

Intervention

Combination Product:
• Efgartigimod PH20 SC
Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Other:
• Placebo PH20 SC
Subcutaneous placebo given by prefilled syringe

Locations

Country	Name	City	State
United States	Advanced Research	Boynton Beach	Florida
United States	American Institute of Research	Los Angeles	California
United States	Butchertown Clinical Trials	Louisville	Kentucky
United States	Martel Eye Medical Group	Rancho Cordova	California

Sponsors (1)

Lead Sponsor	Collaborator
argenx

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants who were proptosis responders		At week 24 of the Double-Blinded Treatment Period
Secondary	Change in proptosis measurement in the study eye from baseline		Up to week 24 of the Double-Blinded Treatment Period
Secondary	Change in the total Graves' Orbitopathy Quality of Life (GO-QoL) score from baseline	Minimum value: 0 (most negative impact on Quality of Life); Maximum value: 100 (No impact on Quality of Life)	Up to week 24 of the Double-Blinded Treatment Period
Secondary	Percentage of participants with a resolution of diplopia (responders)		At week 24 of the Double-Blinded Treatment Period